Abstract
The increasing knowledge regarding breast cancer carcinogenesis has provided possible opportunities to prevent breast cancer. This paper reviews the issues related to breast cancer chemoprevention including the identification of high-risk groups, biomarkers and potential chemopreventive agents. Trials with tamoxifen have clearly shown that the risk of developing estrogen receptor (ER)-positive breast cancer can be reduced at the later stage of this malignancy. However, there was no beneficial effect on ER-negative cancers. The challenge is to find new agents, which achieve same or better efficacy but with fewer side effects. Raloxifene has similar efficacy to tamoxifen, but leads to more favorable histologic profiles of endometrial tumors and fewer gynecologic symptoms and thrombo-embolic events. Adjuvant trials for contralateral tumors suggest that aromatase inhibitors may be able to prevent up to 70-80% of ER-positive breast cancers. This is currently being investigated in two large prevention trials, the IBIS-II trial using anastrozole and the MAP.3 trial using exemestane. We therefore need to discover novel agents for ER-negative breast cancer.
Keywords: Breast cancer, chemoprevention, prevention trials, tamoxifen, aromatase inhibitors, SERMs
Current Enzyme Inhibition
Title: Breast Cancer Chemoprevention: Current Perspectives
Volume: 5 Issue: 4
Author(s): Takeru Oyama, Yumiko Yasui and Takuji Tanaka
Affiliation:
Keywords: Breast cancer, chemoprevention, prevention trials, tamoxifen, aromatase inhibitors, SERMs
Abstract: The increasing knowledge regarding breast cancer carcinogenesis has provided possible opportunities to prevent breast cancer. This paper reviews the issues related to breast cancer chemoprevention including the identification of high-risk groups, biomarkers and potential chemopreventive agents. Trials with tamoxifen have clearly shown that the risk of developing estrogen receptor (ER)-positive breast cancer can be reduced at the later stage of this malignancy. However, there was no beneficial effect on ER-negative cancers. The challenge is to find new agents, which achieve same or better efficacy but with fewer side effects. Raloxifene has similar efficacy to tamoxifen, but leads to more favorable histologic profiles of endometrial tumors and fewer gynecologic symptoms and thrombo-embolic events. Adjuvant trials for contralateral tumors suggest that aromatase inhibitors may be able to prevent up to 70-80% of ER-positive breast cancers. This is currently being investigated in two large prevention trials, the IBIS-II trial using anastrozole and the MAP.3 trial using exemestane. We therefore need to discover novel agents for ER-negative breast cancer.
Export Options
About this article
Cite this article as:
Oyama Takeru, Yasui Yumiko and Tanaka Takuji, Breast Cancer Chemoprevention: Current Perspectives, Current Enzyme Inhibition 2009; 5 (4) . https://dx.doi.org/10.2174/157340809789630271
DOI https://dx.doi.org/10.2174/157340809789630271 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Technological Advances in the Mass Spectrometry-based Nanomedicine Studies: An Insight from Nanoproteomics
Current Pharmaceutical Design Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry Molecular Surgery with Auger Electron-Emitting Radiopharmaceuticals
Current Radiopharmaceuticals Transforming Growth Factor-β: A Molecular Target for the Future Therapy of Glioblastoma
Current Pharmaceutical Design Curcumin has Bright Prospects for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design In Vivo Inhibition of Proteasome Activity and Tumour Growth by Murraya koenigii Leaf Extract in Breast Cancer Xenografts and by Its Active Flavonoids in Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews A Dual Role for Sirtuin 1 in Tumorigenesis
Current Pharmaceutical Design Current Issues in the Utility of Blood Oxygen Level Dependent MRI for the Assessment of Modulations in Tumor Oxygenation
Current Medical Imaging Oligodeoxynucleotide Acid Loaded, NGR-Peptide-Conjugated Polymeric Liposomes: In Vitro and In Vivo Evaluation
Current Nanoscience Relationships Between the Structural Properties of Flavonoids and their Inhibitory Activities Against Matrix Metallopeptidase 9
Letters in Drug Design & Discovery Editorial [Hot topic: Breast Cancer: Novel Therapeutic Targets (Guest Editor: George W. Yip)]
Recent Patents on Anti-Cancer Drug Discovery A Multiwave Imaging Approach for Elastography
Current Medical Imaging Overview of Mechanisms of Cancer Stem Cell Drug Resistance
Current Signal Transduction Therapy Application of 3-methylene- and 3-(monosubstituted)alkylideneoxindoles in the Synthesis of Heterocyclic Compounds
Current Organic Chemistry Intraorganellar Acidification by V-ATPases: A Target in Cell Proliferation and Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Effects of Motivational Interview on Awareness, Attitude, and Practice of Breast Self-examination in High-risk Women: A Clinical Trial Study
Current Women`s Health Reviews Pleiotropic Effects of Cardioactive Glycosides
Current Medicinal Chemistry Potential of Liposomes for Enhancement of Oral Drug Absorption
Current Drug Delivery